PhotoPharmics
Light therapy targeting Parkinson's disease
Nov
2012
Company Event
Initial seed round
Dec
2012
Frazier Event
Frazier VC Seed primary investment
Feb
2017
Frazier Event
Frazier VC primary investment convertible notes
Feb
2017
Company Event
$2.3M equity
Apr
2018
Frazier Event
Frazier VC primary investment convertible notes
May
2019
Frazier Event
Frazier VC primary investment convertible notes
Apr
2020
Company Event
FDA Breakthrough Device Designation
May
2020
Frazier Event
Frazier VC primary investment convertible notes
Nov
2023
Company Event
$16M investment round
Apr
2025
Company Event
$6M Series B extension
Capital Events Timeline
Company Overview
PhotoPharmics is a clinical-stage medical device company developing specialized phototherapy for neurodegenerative diseases, initially focused on Parkinson's disease.
Why We Invested
PhotoPharmics uses a non-invasive, at-home phototherapy platform with a distinct position in neurodegenerative care and significant unmet need.
Investment Vehicle
Frazier Family Investment
Investor
Frazier VC
Founded
2011
Sector
Healthcare & Life Sciences
Legal Name
PhotoPharmics, Inc.
Status
Active
Other Investors
Kickstart Fund